Rheumatoid arthritis Market Size

Rheumatoid Arthritis Market Overview

The Rheumatoid arthritis market Size was valued at USD 67.55 billion in 2023 and is projected to grow from USD 72.10 Billion in 2024 to USD 115.75 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.40% during the forecast period (2024-2032). The growing prevalence of arthritis and associated joint issues are the key market drivers enhancing market growth.

The major factors driving growth of the rheumatoid arthritis drugs market are the increasing prevalence of RA, the rising demand for RA drugs, the expiration of patents and the entry of biosimilar drugs, the rising geriatric population, the rising adoption of conventional DMARDs, and government initiatives aimed at raising awareness of RA symptoms.

Government initiatives to research new treatments for rheumatoid arthritis have also contributed to the expansion of the worldwide RA medicine market. The worldwide market for rheumatoid arthritis medications is expanding, and the government is helping it do so by enlisting the help of important industry participants.

More people are talking about RA medications, more research is being done on them, healthcare reform is on the rise, and more people are using them as a result. The growing elderly population and the accompanying increase in demand for DMARDs also help propel the industry forward. It is more likely that this patient population will benefit therapeutically from a combination of disease-modifying antirheumatic drugs and biologics. As a result, the market for rheumatoid arthritis medications is shifting toward combination therapies that provide synergistic advantages.

Market expansion is also aided by developments in cutting-edge biologics, an increase in healthcare spending, rising consumer incomes, and more availability of affordable, high-quality medicine for the world's poor and middle classes. The market for rheumatoid arthritis medications is expected to expand at a rapid clip throughout the forecast period, thanks to rising knowledge about early screening and treatment.

July 2023: Biocon Biologics' Hulia (adalimumab-fkjp) injectable, a biosimilar of Humira, was made available in Europe and Canada for five years prior to its debut in the United States in July 2023. Adalimumab is a monoclonal antibody that has been shown to be effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions. Biocon Biologics has successfully gained clearance for its biosimilars in the United States, Europe, and more than a hundred other countries.

Biocon Biologics Ltd, which is part of Biocon Ltd, in July 2023 announced that they had successfully brought HULIO (adalimumab fijp) injection into the market in America. It works like Humira (adalimumab) and helps alleviate rheumatoid arthritis.

In July 2022, Hikma partnered with Celltrion to expand YUFLYMA (CT-P17) into North Africa and the Middle East. Rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease are among a number of conditions treated by CT-P17: it is biosimilar to adalimumab but has higher concentration, smaller size and does not contain citrate. It also reduces pain on injection as compared to CT-P17 and even possess properties that help reduce discomfort.

Pfizer Inc. said in February 2022 that US Food and Drug Administration (FDA) agreed to evaluate their application for ABRILADA (adalimumab-afib). They would like it declared as a generic drug similar to Humira (adalimumab), which can substitute for the original.

Furthermore, Lupin launched generic Duexis tablets in September 2021, used in the treatment of symptoms associated with rheumatoid arthritis, such as osteoarthritis in the United States market.

The manufacturers of Xcimzane are Biogen Inc., who have partnered with Xbrane Biopharma AB in February 2022 to design what will be utilized for this purpose and manufacture them later on. This drug is still undergoing testing but it wants to replicate CIMZIA (certolizumab pegol), another alternative useable in treating rheumatoid arthritis.

The Indian company Lupin began selling branded competition for Arava in September 2020; specifically its leflunomide generic version was made available at retail stores throughout the US territory. Consequently, more patients may opt for rheumatoid arthritis treatments.

For example, in July 2020, Mylan announced that Hulio, a biosimilar to Humira, had been approved by the FDA. It is a TNF inhibitor used to treat people with rheumatoid arthritis (RA), juvenile degenerative arthritis (JDA), psoriatic arthritis (PA), reactive arthritis (ReA) spondylitis, adult Crohn’s disease (ACD), gastrointestinal disorders and psoriatic arthritis. The global launch of such combinations would trigger the growth of the rheumatoid arthritis market on a universal scale. The advancement of technology is expected to increase the demand for combination therapies.

Rheumatoid Arthritis Market Trends

Growing Prevalence of Rheumatoid Arthritis to boost the market growth

The growing prevalence of rheumatoid arthritis is mainly due to the aging population. Rheumatoid arthritis is surging due to an unhealthy lifestyle, enriched metabolic disorderliness and age, a family background of joint disease, and increased adiposity. To nourish their position in this market, producers are working on making alliances with other companies. New technologies to beat the therapeutic potential of antibodies, such as bi-specific preventives, and novel targets, such as JAK enzymes, have given rheumatoid arthritis therapy providers new options.

Further, the majority of players have a combination of Disease-modifying antirheumatic drug medication in development, and the majority of these projects involve combining new biologic therapy with adalimumab, the most popular antirheumatic drug. Moreover, the expansion and upgrading of well-developed healthcare infrastructure will be critical to the country's market development.

Additionally, the aging population is mainly accountable for the rising incidences of rheumatoid arthritis. Therefore, such a medical condition related to it has enhanced the market CAGR of Rheumatoid Arthritis across the globe in recent years.

However, the advances in sophisticated biologics, high purchasing power, huge healthcare expenditure, and global access to higher quality medications for Average and poor-class families are all contributing factors that are another factor fetching the rheumatoid arthritis market revenues. There were around 210 countries that have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at significant risk of developing severe symptoms and consequences which will lead to increased Rheumatoid arthritis Market Size

Rheumatoid Arthritis Market Segment Insights

Rheumatoid Arthritis Drug Type Insights

The market segments of rheumatoid arthritis, based on drug type, this category is segmented into nonsteroidal anti-inflammatory drug type, steroids, biological agents, and others. The increasing launch of novel biologics and growing penetration of generic drugs are estimated to provide a significant boost to the market. Biologic drugs are favored over biosimilars by physicians for the treatment of RA and are expected to dominate the market throughout the forecast horizon.

For instance, the introduction of Olumiant by Eli Lilly and Company in 2017 is likely to fuel revenues in Japan. Likewise, Upadacitinib, a novel JAK1-selective inhibitor by AbbVie, is awaiting approval by 2019. Lately approved biologics such as Xeljanz and Kevzara are poised to have strong market penetration because of the presence of a favorable reimbursement scenario. with respect to the market revenue of rheumatoid arthritis.

April 2019: Cipla Ltd. purchased a 30% stake in Brandmed, a South African company, to expand its business. Cipla Medpro's portfolio will be intensified by the acquisition, which combines the company's potential with Brandmed's creative, patient-centric approach to healthcare.

Rheumatoid Arthritis Diagnosis Insights

The rheumatoid arthritis market data, based on diagnosis, has been bifurcated by C - reactive protein Test, CCP, ESR test, and others. This blood test checks for anti-CCP antibodies that tend to appear in many people with rheumatoid arthritis. Furthermore, anti-CCP can appear before RA symptoms develop, which can assist doctors in diagnosing the disease early. This test's results, accompanied by RF blood tests, are very useful in verifying a RA diagnosis. However, it is more significant to know that some people have rheumatoid arthritis even with normal tests. Hence, this preferable use of CCP helps in rising market growth. The global surgery into minimally invasive spine surgery and open spine surgery.

October 2021: Cadila Pharmaceuticals (Cadila) launched two similar biologics in the Indian market, namely NuPTH, a teriparatide biologic, and Cadalimab, a similar biologic of the auto-immune treatment adalimumab. This approval has further broadened the growth opportunity for the Rheumatoid Arthritis industry.

Figure 2: Rheumatoid arthritis market, by Surgery, 2021 & 2030 (USD Million)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Additionally, due to enhanced treatment regarding early treatment and screening of rheumatoid arthritis, the global rheumatoid arthritis drugs market is predicted to grow quickly and shift the market outlook. As a result, growing advancements in biologics are making lucrative opportunities for the growth of the global rheumatoid arthritis drugs market.

Rheumatoid Arthritis Treatment Insights

Based on treatment, the global rheumatoid arthritis industry has been segmented into synovectomy, tendon pair, joint fusion, and others. Few people find wearing a splint for a shorter time period around joint pain and swelling. Most people use splints on wrists and hands but also on ankles and feet. People must consult a doctor before physical or occupational therapy while wearing a splint.

Moreover, you can protect your joints by using self-help devices, such as items with a huge grip, zipper pullers, or long-handled shoehorns, using devices that assist with activities of daily living, such as an adaptive toothbrush or silverware, using devices to help you get on and off chairs, toilet seats, and beds, choose activities that put less stress on joints, such as limiting the use of the stairs or taking rest periods while walking long distances and maintaining a healthy weight to help lower the stress on your joints.  

August 2023: Generic Indomethacin suppositories for moderate to severe rheumatoid arthritis will be available for sale in the United States by August 2023, according to a press release from Zydus Lifesciences Ltd. The firm said in a regulatory filing that it has received clearance from the US Food and Drug Administration (USFDA) to produce and sell Indomethacin suppositories 50 mg in strength.

May 2023: Peresolimab met the primary objective for effectiveness in a phase 2a trial of rheumatoid arthritis (RA) conducted by Eli Lilly and Company and published in May 2023. The incidence of adverse events were similar in the peresolimab and placebo groups. These findings provide the first clinical evidence that activating the endogenous PD-1 inhibitory pathway may be a useful strategy for treating rheumatologic diseases. Peresolimab's

Rheumatoid Arthritis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Rheumatoid Arthritis market is expected to show a significant CAGR growth over the forecast period. North America recorded more than 55.0% of the rheumatoid arthritis therapeutics market in 2016. Increased awareness of disease remittance therapies amongst patients, growing prevalence of RA, and high private and public healthcare expenses are wheeling the growth of the region.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: RHEUMATOID ARTHRITIS MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's rheumatoid arthritis market accounts for the second-largest market share due to the availability of treatment facilities, government backing for the growth of the healthcare industry, an aging population, and an increase in rheumatoid arthritis and osteoarthritis.

Further, the German market of rheumatoid arthritis held the largest market share, and the UK market of rheumatoid arthritis was the fastest-growing market in the European region.

The Asia-Pacific rheumatoid arthritis Market is expected to grow at the fastest CAGR from 2022 to 2030. The rising adoption of urban lifestyle is leading to expanding base of patients in the region. This, paired with increasing healthcare spending, is anticipated to propel the market in APAC. Favorable policies for biosimilars are estimated to boost demand for therapies over the forecast period. Further, China's market of rheumatoid arthritis held the largest market share, and the Indian market of rheumatoid arthritis was the fastest-growing market in the Asia-Pacific region.

Moreover, easily accessible quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

Rheumatoid Arthritis Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to fuel their product lines, which will help the market of rheumatoid arthritis grow even more. Participants in the market are also taking strategic measures to grow their business worldwide, with key market developments such as new product launching, periodic partnerships, mergers and acquisitions, huge investments, and collaboration with other organizations. Competitors in the rheumatoid arthritis industry must offer low-cost meds to expand and run in an increasingly competitive market environment.

One of the primary business strategies adopted by manufacturers in the global rheumatoid arthritis industry to benefit clients and expand the market sector is to manufacture locally to reduce costs. In recent years, the rheumatoid arthritis industry has provided medication with some of the most crucial benefits. The rheumatoid arthritis market's major players are Eli Lilly, and Company (U.S.), Bristol-Myers Squibb Company (U.S.), Hoffmann-La Roche Ltd (Switzerland), and others who are working on expanding the market demand by investing in research and development activities.

Lilly was founded in 1876 by Colonel Eli Lilly, a man engaged in creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable things. His statement to the generations of employees who have followed was this: "speak what you find here and make it better." More than 145 years later, they remain engaged in their vision through every feature of the business and the patient they serve, starting with those who take the company's medicines and extending to healthcare professionals, employees, and the communities in which we live.

Bristol-Myers Squibb Company’s legacy of innovation started in the early 1800s when its leaders made it their goal to bring better health solutions to people who needed those most. Today, they are continuing that tradition by using the newest science and technology to improve lives through the research and development of new medicines for serious disorders. Their mission was to discover, develop and deliver the newest medicines that help patients prevail over serious diseases and aimed at being the world’s leading Biopharma Company that transforms patients’ lives through science.

Key Companies in the market of rheumatoid arthritis include

• Pfizer Inc (U.S)


• Eli Lilly and Company (U.S)


• Bristol-Myers Squibb Company (U.S)


• Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Bayer AG (Germany)


• Vertex Pharmaceuticals Incorporated (U.S)


• Sanofi (France)


• Cipla Ltd. (India)


• AstraZeneca (U.K), among others

Rheumatoid Arthritis Industry Developments

Pfizer introduced in November 2019 that the FDA had approved its biosimilar, abriladaTM, for a variety of inflammatory disorders, including RA.

Bayer AG gave a statement in 2020 that it would enlarge its Beijing supply center by investing roughly USD 59 million in the making of a recent production and supply facility at Beijing Economic-Technological Development.

Rheumatoid Arthritis Market Segmentation

Rheumatoid Arthritis Drug Type Outlook

• Nonsteroidal anti-inflammatory drug type


• Steroids


• Biologic agents

Rheumatoid Arthritis Diagnosis Outlook

• C-Reactive Protein


• Test


• CCP


• ESR test

Rheumatoid Arthritis Treatment Outlook

• Synovectomy


• Tendon repair


• Joint fusion

Rheumatoid Arthritis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America